Oncopeptides AB (publ)

LSE:0RN4 Stock Report

Market Cap: SEK 319.3m

Oncopeptides Past Earnings Performance

Past criteria checks 0/6

Oncopeptides has been growing earnings at an average annual rate of 25.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 10.4% per year.

Key information

25.6%

Earnings growth rate

35.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate10.4%
Return on equity-208.2%
Net Margin-1,043.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oncopeptides makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0RN4 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2427-282197111
30 Jun 2421-26319095
31 Mar 2439-246189105
31 Dec 2335-249188107
30 Sep 2330-259178131
30 Jun 2327-307178175
31 Mar 239-310154182
31 Dec 228-338142218
30 Sep 22-14-641304345
30 Jun 2241-1,330464444
31 Mar 2299-1,294681567
31 Dec 21118-1,430874680
30 Sep 21140-1,549907727
30 Jun 2186-1,155889771
31 Mar 2119-1,532788831
31 Dec 200-1,595654866
30 Sep 200-1,327494792
30 Jun 200-1,133364750
31 Mar 200-904262655
31 Dec 190-741199548
30 Sep 190-608146482
30 Jun 190-512116399
31 Mar 190-485124366
31 Dec 180-411106314
30 Sep 180-368100276
30 Jun 180-32580255
31 Mar 180-24847205
31 Dec 170-25050198
30 Sep 170-24352180
30 Jun 170-21653152
31 Mar 170-17238124
31 Dec 160-1252590
31 Dec 150-621044

Quality Earnings: 0RN4 is currently unprofitable.

Growing Profit Margin: 0RN4 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0RN4 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare 0RN4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0RN4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0RN4 has a negative Return on Equity (-208.17%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Robert BurnsH.C. Wainwright & Co.